2) GLP 1s are no longer just a trend they're the top tier
While injectable GLP-1s work well for weight loss, keeping the weight off after discontinuing the therapies is challenging
When treating a chronic disease like obesity, it is key to have options throughout the weight loss journey to health, Dr
In the ATTAIN-MAINTAIN trial, 205 patients taking tirzepatide and 171 patients taking semaglutide were randomized to take orforglipron or placebo (no active drug) daily for a year
Merck, Roche, AstraZeneca, and Lilly all rose in the rankings with Lilly pushing GSK out of the top 10
Approved GLP-RAs In 2005, Exendin-4 (Exenatide/ BYETTA), the world's first GLP-1RA, was approved by the FDA for the adjuvant treatment of type 2 diabetes with two injections per day (BID)